Business Wire

Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline

BOSTON--(BUSINESS WIRE)--Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced the closing ...
Morningstar

Ensoma Unveils Three Programs Leveraging In Vivo Hematopoietic Stem Cell Engineering Platform to Target Genetic, Immune and Oncological Diseases

Lead program advancing to IND filing in H1 2025 for the treatment of X-linked chronic granulomatous disease (X-CGD) will be first in vivo HSC-directed therapy tested in humans Preclinical data to be ...
Yahoo Finance

Ensoma Presents Preclinical Data Demonstrating Potential of In Vivo, HSC-derived CAR-M, NK, and T Platform for Solid Tumors at SITC 2025

Remodeled the cold solid tumor microenvironment, marked by macrophage M1 polarization, increased lymphocyte recruitment, and production of inflammatory cytokines and chemokines.
Yahoo Finance

Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline

Company’s Phase 1/2 Clinical Trial of EN-374 in X-linked Chronic Granulomatous Disease is Now Open for Patient Enrollment BOSTON, September 22, 2025--(BUSINESS WIRE)--Ensoma, an in vivo hematopoietic ...